3,511 results found

On January 31, 2023, the Patented Medicine Prices Review Board (PMPRB) announced the latest edition of CompassRx, an annual report which contains information...

On June 26, 2024, the Patented Medicine Prices Review Board (PMPRB) released a Discussion Guide for its Phase 2 Consultations on its New Guidelines

On June 20, 2023, the Patented Medicine Prices Review Board (PMPRB) released a proposal to amend the Interim Guidance...

The PMPRB has just released revised draft Guidelines operationalizing the amended Patented Medicines Regulations, simultaneously beginning a 30-day consultation period.

On July 31, 2021, the Minister of Health provided notice of proposed amendments to the Food and Drug Regulations and the Medical Devices Regulations.

The OHIP+ program, also known as Children and Youth Pharmacare program, was implemented on January 1, 2018 by the Province of Ontario to provide free prescription drug coverage for all children and youth 24 years...

On June 15, 2018, Health Canada announced the publication of proposed Regulations Amending the Food and Drug Regulations and the Regulations Amending the Medical Devices Regulations.

On August 16, 2022, LiveFit North America Inc. operating as Ethey ("Ethey") announced that it had acquired Puppy Gang Fresh Foods Ltd. ("Puppy Gang").

Historically, when purchasing a property in Ontario, it was not uncommon for a vendor to represent and warrant in the agreement of purchase

The US FDA has now approved a biosimilar version of infliximab, which is a chimeric human-mouse monoclonal antibody.

On May 17th 2017, Health Canada announced changes to the Food and Drug Regulations regarding the use of antimicrobial drugs in animals.

The Federal Cannabis Act (the "Act") came into force on October 17, 2018 and officially marked the legalization of recreational cannabis in Canada.

Private equity investment in the food and beverage industry continues to steadily increase, driven in part by evolving consumer preferences and a heightened focus on sustainability.

On July 17, 2019, SOL Global Investments Corp. (CSE: SOL (OTCPK: SOLCF) ) (Frankfurt: 9SB) announced a US$6.5 million capital infusion in its portfolio company CannCure Investments Inc.

The report also indicates that approximately 10-20% of Canadians do not have adequate coverage.

As previously reported, the Federal Court of Appeal dismissed two decisions relating to paliperidone palmitate (Janssen's INVEGA SUSTENNA)...

The Supreme Court of Canada has today granted AstraZeneca leave to appeal a Federal Court of Appeal decision, affirming a trial decision invalidating its patent relating to its successful esomeprazole drug (NEXIUM) for lack of utility.